2025-09-10T08:56:06+00:00 2024-12-31 135381590 BDO USA 8401 GREENSBORO DR STE 800 MCLEAN VA 221023599 990 2024-01-01 526063009 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA FDN INC PHAR 2025727756 670 MAINE AVENUE SW 1000 WASHINGTON DC 20024 AMY MILLER PRESIDENT 2025727755 2025-09-10 true TODD TERESCO P00247720 7038930600 2025-09-10 2024 2025-03-06 01:10:19Z X AMY MILLER 670 MAINE AVENUE SW 1000 WASHINGTON DC 20024 13893480 false X WWW.PHRMAFOUNDATION.ORG X 1965 DC THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE DRIVEN HEALTH CARE. 8 8 4 80 0 3576216 3705380 0 0 668514 587753 0 0 4244730 4293133 2952608 3479307 0 0 1052004 1136663 0 0 3325 361391 365891 4366003 4981861 -121273 -688728 24481309 27568119 404521 1540685 24076788 26027434 X THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE-DRIVEN HEALTH CARE. false false 1270844 1020832 0 DRUG DISCOVERY - SUPPORTS EARLY CAREER RESEARCHERS WHOSE RESEARCH CAN HELP ACCELERATE BIOLOGICAL VALIDATION OF POTENTIAL DRUG TARGETS. 1183448 942224 0 VALUE ASSESSMENT-HEALTH OUTCOMES RESEARCH - SUPPORTS RESEARCHERS INVESTIGATING CHALLENGES IN EVALUATING THE DELIVERY, SAFETY, EFFECTIVENESS, AND VALUE OF HEALTH CARE INTERVENTIONS. 1051264 851250 0 DRUG DELIVERY - SUPPORTS EARLY CAREER RESEARCHERS STUDYING WAYS TO OPTIMIZE DRUG COMPOSITION, DOSAGE, AND DELIVERY TO MAKE TREATMENTS SAFER, MORE EFFECTIVE, AND EASIER TO MANAGE FOR PATIENTS. 675841 540000 0 TRANSLATIONAL MEDICINE - SUPPORTS EARLY CAREER INVESTIGATORS CONDUCTING NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATEMENT, AND PREVENTION OF DISEASE. 223870 125001 0 OTHER PROGRAMS EXPENSES 899711 665001 4405267 true true false false false false false false false false true false false false true true true false false false false false false false false false false false true true false false false false false false false false false false false false false false false false false false false false true 53 0 true 4 true false false false false false false false false false false false false X 8 8 false false false false false true false true true false false false true true true true true true true true false false CA CT IL MD MA NJ NY NC PA X KIMBERLY SIDHU 2028353400 670 MAINE AVENUE SW SUITE 1000 WASHINGTON DC 20024 ANDREW PLUMP MD PHD CHAIRMAN 1.0 0 X X 0 0 0 DONATELLO CROCETTA TREASURER (AS OF 12/24) 1.0 0 X X 0 0 0 IRIS LOEW-FRIEDRICH MD TREASURER (THRU 12/24) 1.0 0 X X 0 0 0 AIDA HABTEZION MD MSC FRCP DIRECTOR 1.0 0 X 0 0 0 ARAN MAREE MB BCH MRCIP DIRECTOR (THRU 10/24) 1.0 0 X 0 0 0 DANIEL SKOVRONSKY MD PhD DIRECTOR 1.0 0 X 0 0 0 GEORGE ADDONA PHD DIRECTOR 1.0 0 X 0 0 0 JOHN REED MD PhD DIRECTOR (AS OF 12/24) 1.0 0 X 0 0 0 LORI REILLY Esq EX OFFICIO MEMBER 1.0 0 X 0 0 0 MAHA RADHAKRISHNAN MD DIRECTOR (THRU 03/24) 1.0 0 X 0 0 0 ROBERT PLENGE MD PHD DIRECTOR 1.0 0 X 0 0 0 AMY MILLER PRESIDENT 37.5 0 X 515068 0 72837 EMILY ORTMAN SENIOR DIRECTOR 37.5 0 X 198869 0 58730 JOANNE WESTPHAL DIRECTOR 37.5 0 X 178835 0 36213 892772 0 167780 3 false true false O'CONNOR CONSULTING SERVICES LLC 6507 MARJORY LANE BETHESDA MD 20817 ACCT, FINANCIAL STATEMENT & TAX PREPARATION 131808 1 3705380 3705380 0 0 0 0 0 600608 600608 0 0 9587492 9600347 -12855 0 -12855 -12855 0 0 0 0 0 0 4293133 0 0 587753 3479307 3479307 587906 416276 171630 334705 236993 97712 72659 51447 21212 77147 54625 22522 64246 45490 18756 35316 35316 22367 22367 178693 33400 145293 0 8169 8169 946 680 266 14794 14436 358 28332 14148 14184 19251 19251 32726 23172 9554 10228 7242 2986 DUES/ PUBLICATIONS/ PROJECTS 4807 631 851 3325 BANK/ PAYROLL CHARGES 10262 10262 0 0 0 0 4981861 4405267 573269 3325 1396883 2768034 0 0 0 20886 18563 98178 38180 92724 59998 22970816 24721524 0 0 0 0 24481309 27568119 374751 1517703 0 29770 22982 404521 1540685 X 24076788 26027434 24076788 26027434 24481309 27568119 X -688728 2601976 37398 X X false true true false X 3937859 2764822 3535607 3576216 3705380 17519884 0 0 3937859 2764822 3535607 3576216 3705380 17519884 11360638 6159246 477282 407496 460897 496762 600608 2443045 0 0 0 0 0 0 0 19962929 0 0.30853 0.3068 X Schedule A, Part II PART II, SECTION C, LINE 17A, FACTS AND CIRCUMSTANCES TEST: THE FOUNDATION CONTINUES TO SOLICIT FUNDS FROM NEW SUPPORTERS IN THE PHARMACEUTICAL RESEARCH FIELD USING A VARIETY OF OUTREACH METHODS. THE FOUNDATION PROMOTES ITS GRANTS AND AWARDS PROGRAM AND NETWORKS WITH INDUSTRY PEERS AND DONORS. FOUNDATION STAFF CREATE OR UPDATE FUNDRAISING RELATED MATERIALS ANNUALLY. THE FOUNDATION'S BOARD OF DIRECTORS CONSISTS OF RESEARCH AND DEVELOPMENT EXECUTIVES AND CHIEF MEDICAL OFFICERS OF BIOPHARMACEUTICAL COMPANIES, ALL OF WHOM HAVE SPECIALIZED KNOWLEDGE AND EXPERTISE IN THE FIELD OF PHARMACEUTICAL RESEARCH. THE FOUNDATION'S BOARD MEMBERS REGULARLY IDENTIFY FUNDRAISING OUTREACH STRATEGIES AND ASSIST STAFF IN THEIR IMPLEMENTATION. THE FOUNDATION DISTRIBUTES A REGULAR NEWSLETTER TO PROMOTE THE FOUNDATION AND ENGAGE WITH POTENTIAL NEW DONORS. THE FOUNDATION OPERATES IN THE PUBLIC'S INTEREST BY ADMINISTERING A GRANTS AND AWARDS PROGRAM AVAILABLE TO ELIGIBLE CANDIDATES ACROSS THE UNITED STATES. THE FOUNDATION ACTIVELY SEEKS WAYS TO EXPAND OUTREACH AND INCREASE APPLICATION RATES AMONG HISTORICALLY UNDERREPRESENTED GROUPS AND SUPPORTS THE PUBLICATION OF AWARDEE RESEARCH FINDINGS. THE FOUNDATION PROVIDES FREE EDUCATIONAL RESOURCES TO THE GENERAL PUBLIC THROUGH ITS WEBSITE AND WEBINARS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 98178 38180 59998 59998 Federal Income Taxes INTERCOMPANY SETTLEMENT 22982 22982 X 6937626 2601976 64884 0 2666860 4270766 22367 0 22367 4293133 4986980 64884 -37398 27486 4959494 22367 0 22367 4981861 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND CONCLUDED THAT THE FOUNDATION HAS NOT TAKEN ANY UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS. AT A MINIMUM, THE TAX PERIODS ENDED DECEMBER 31, 2021 AND LATER ARE OPEN FOR EXAMINATION BY TAXING AUTHORITIES. Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 REFUNDED GRANTS - -37398 true DRUG DISCOVERY 29 1020832 VALUE ASSMT-HEALTH OUTCOMES RSRCH 25 942224 DRUG DELIVERY 18 851250 TRANSLATIONAL MEDICINE 12 540000 DIGITAL HEALTH TECHNOLOGY 6 125001 Schedule I, Part III DRUG DISCOVERY - SUPPORTS EARLY CAREER RESEARCHERS WHOSE RESEARCH CAN HELP ACCELERATE BIOLOGICAL VALIDATION OF POTENTIAL DRUG TARGETS. VALUE ASSESSMENT-HEALTH OUTCOMES RESEARCH - SUPPORTS RESEARCHERS INVESTIGATING CHALLENGES IN EVALUATING THE DELIVERY, SAFETY, EFFECTIVENESS, AND VALUE OF HEALTH CARE INTERVENTIONS. DRUG DELIVERY - SUPPORTS EARLY CAREER RESEARCHERS STUDYING WAYS TO OPTIMIZE DRUG COMPOSITION, DOSAGE, AND DELIVERY TO MAKE TREATMENTS SAFER, MORE EFFECTIVE, AND EASIER TO MANAGE FOR PATIENTS. TRANSLATIONAL MEDICINE - SUPPORTS EARLY CAREER INVESTIGATORS CONDUCTING NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATEMENT, AND PREVENTION OF DISEASE. DIGITAL HEALTH TECHNOLOGY - SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. THE GRANTS AND FELLOWSHIPS ARE AWARDED WITH INFORMATION ON HOW THE FUNDS MAY BE SPENT AND ADMINISTERED. THE SECOND YEAR OF FUNDING, IF APPLICABLE, IS CONTINGENT UPON A SATISFACTORY REVIEW OF THE AWARD RECIPIENT'S PROGRESS DURING THE FIRST TEN MONTHS OF FUNDING. A PROGRESS REPORT IS DUE TO THE FOUNDATION PRIOR TO THE BEGINNING OF THE SECOND YEAR OF FUNDING. THE PROGRESS IS ASSESSED BY THE ADVISORY COMMITTEE. THE DECISION TO CONTINUE THE FUNDING IS BASED ON ADHERENCE TO THE GOALS OF THE PROGRAM AND THE ORIGINALLY PROPOSED RESEARCH ON WHICH THE AWARD WAS BASED. IN ADDITION TO THE PROGRESS REPORT, THE FOUNDATION MUST RECEIVE CERTIFICATION FROM THE THESIS ADVISOR OR MENTOR THAT SATISFACTORY PROGRESS IS BEING ACHIEVED FOR PRE-DOCTORAL AND POSTDOCTORAL FELLOWSHIPS. A FINANCIAL REPORT IS ALSO DUE TO THE FOUNDATION AFTER THE FIRST YEAR OF FUNDING AND FOLLOWING THE END OF THE FUNDING PERIOD FOR ALL AWARDS. THE INSTITUTION MUST STIPULATE THE AMOUNT OF FUNDS RECEIVED BY THE UNIVERSITY, HOW THE FUNDS HAVE BEEN USED/SPENT AND IF THERE IS A REMAINING BALANCE ON THE ACCOUNT. X X false false false false false false false false false AMY MILLER PRESIDENT 357131 0 155987 0 1950 0 34500 0 38337 0 587905 0 0 0 EMILY ORTMAN SENIOR DIRECTOR 162989 0 32823 0 3057 0 18912 0 39818 0 257599 0 0 0 JOANNE WESTPHAL DIRECTOR 154130 0 20880 0 3825 0 18956 0 17257 0 215048 0 0 0 Form 990, Part III, Line 4a-4c Description of program services (Expenses $ 675,841 including grants of $ 540,000)(Revenue $ 0) TRANSLATIONAL MEDICINE - SUPPORTS EARLY CAREER INVESTIGATORS CONDUCTING NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATEMENT, AND PREVENTION OF DISEASE. Form 990, Part III, Line 4a-4c Description of program services (Expenses $ 223,870 including grants of $ 125,001)(Revenue $ 0) OTHER PROGRAMS EXPENSES Form 990, Part VI, Line 15 PROCESS TO ESTABLISH COMPENSATION OF TOP MANAGEMENT OFFICIAL MERIT RAISES AND BONUSES ARE DETERMINED IN ACCORDANCE WITH PHRMA POLICY BASED ON STAFF EVALUATIONS, AND RECOMMENDATIONS ARE FORWARDED TO THE PRESIDENT FOR REVIEW. OVERALL PERFORMANCE OF THE PRESIDENT OF THE FOUNDATION, INCLUDING MERIT RAISES AND BONUSES, IS ALSO DETERMINED IN ACCORDANCE WITH PHRMA POLICY BASED ON STAFF EVALUATIONS BY THE EX-OFFICIO MEMBER OF THE FOUNDATION BOARD. THIS EVALUATION IS FORWARDED AS ARE RECOMMENDATION TO THE CHAIR AND VICE CHAIR OF THE FOUNDATION BOARD FOR FINAL APPROVAL OF THE PRESIDENT'S PERFORMANCE, INCLUDING COMPENSATION/BONUS. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body THE CHIEF OPERATING OFFICER OF THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), A SECTION 501(C)(6) TRADE ASSOCIATION THAT HAS A HISTORIC AND CONTINUING RELATIONSHIP WITH THE FOUNDATION, IS AN EX-OFFICIO MEMBER OF THE FOUNDATION'S BOARD OF DIRECTORS. FOUNDATION DIRECTORS MUST BE RESEARCH AND DEVELOPMENT EXECUTIVES OR CHIEF MEDICAL OFFICERS OF COMPANIES THAT ARE MEMBERS OF PHRMA, BUT ARE ELECTED BY THE FOUNDATION BOARD ITSELF. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FOUNDATION FORM 990 IS PREPARED BY BDO USA, CPAS, AND REVIEWED INTERNALLY BY KEY FINANCIAL MANAGEMENT AND THE FOUNDATION'S PRESIDENT. A COPY OF THE 990 IS PROVIDED TO THE BOARD OF DIRECTORS TO REVIEW PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES OF THE FOUNDATION MUST REPORT POTENTIAL AND ACTUAL CONFLICTS AS THEY ARISE. IN ADDITION, THEY ARE REQUIRED TO SIGN AN ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT. WHEN A POTENTIAL CONFLICT OF INTEREST IS DISCLOSED TO, OR OTHERWISE COMES TO THE ATTENTION OF, THE PRESIDENT, THE CHAIR OF THE BOARD OR A NON-AFFECTED DIRECTOR, HE OR SHE SHALL CONSIDER ALL THE RELEVANT CIRCUMSTANCES AND SHALL DETERMINE WHETHER THE ARRANGEMENT IS POTENTIALLY HARMFUL TO THE BEST INTERESTS OF THE FOUNDATION. IF THE ARRANGEMENT IS FOUND NOT TO BE HARMFUL, THEN THE ARRANGEMENT MAY BE AUTHORIZED OR APPROVED; OTHERWISE, THE DIRECTOR, OFFICER OR KEY EMPLOYEE WHO IS INVOLVED OR EXPECTS TO BE INVOLVED IN THETHE ARRANGEMENT SHALL BE NOTIFIED THAT THE ARRANGEMENT IS NOT AUTHORIZED OR APPROVED AND, IF ALREADY IN EXISTENCE, SHOULD BE TERMINATED. THE PRESIDENT SHALL AUTHORIZE OR APPROVE AN ARRANGEMENT ONLY AFTER CONSULTING WITH THE CHAIR OF THE BOARD. THE CHAIR OF THE BOARD SHALL AUTHORIZE OR APPROVE AN ARRANGEMENT ONLY UPON A VOTE OF A MAJORITY OF UNINVOLVED DIRECTORS. Form 990, Part VI, Line 19 Required documents available to the public THE FOUNDATION DOES NOT MAKE ITS GOVERNING DOCUMENTS OR FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. Form 990, Part VII, Section A 1a THE ORGANIZATION IS AMENDING ITS FORM 990 DUE TO A SOFTWARE ISSUE TO CORRECT THE PREVIOUSLY UNDERREPORTED COMPENSATION FOR THREE INDIVIDUALS: AMY MILLER (OFFICER), EMILY ORTMAN (HIGHEST COMPENSATED EMPLOYEE), AND JOANNE WESTPHAL (HIGHEST COMPENSATED EMPLOYEE). FORM 990, PART VII, SECTION A: ON THE ORIGINALLY FILED RETURN, THE REPORTABLE COMPENSATION FROM THE ORGANIZATION (COLUMN D) AND ESTIMATED AMOUNT OF OTHER COMPENSATION FROM THE ORGANIZATION AND RELATED ORGANIZATIONS (COLUMN F) FOR THESE INDIVIDUALS WERE SIGNIFICANTLY UNDERSTATED. THE ORIGINAL AMOUNTS REPORTED WERE AS FOLLOWS: * AMY MILLER: $5,151 (COLUMN D), $728 (COLUMN F) * EMILY ORTMAN: $1,989 (COLUMN D), $587 (COLUMN F) * JOANNE WESTPHAL: $1,788 (COLUMN D), $363 (COLUMN F) ON THE AMENDED RETURN, THE CORRECTED COMPENSATION AMOUNTS ARE: * AMY MILLER: $515,068 (COLUMN D), $72,837 (COLUMN F) * EMILY ORTMAN: $198,869 (COLUMN D), $58,730 (COLUMN F) * JOANNE WESTPHAL: $178,835 (COLUMN D), $36,213 (COLUMN F) SCHEDULE J, PART II: BECAUSE THE ORIGINALLY REPORTED COMPENSATION FOR THESE INDIVIDUALS WAS BELOW THE $150,000 THRESHOLD, SCHEDULE J, PART II WAS NOT COMPLETED ON THE ORIGINAL RETURN. WITH THE CORRECTED COMPENSATION AMOUNTS, SCHEDULE J, PART II IS NOW COMPLETED FOR EACH INDIVIDUAL AS FOLLOWS: * AMY MILLER: BASE COMPENSATION: $357,131 BONUS AND INCENTIVE COMPENSATION: $155,987 OTHER REPORTABLE COMPENSATION: $1,950 RETIREMENT AND OTHER DEFERRED COMPENSATION: $34,500 NONTAXABLE BENEFITS: $38,337 TOTAL: $587,905 * EMILY ORTMAN: BASE COMPENSATION: $162,989 BONUS AND INCENTIVE COMPENSATION: $32,823 OTHER REPORTABLE COMPENSATION: $3,057 RETIREMENT AND OTHER DEFERRED COMPENSATION: $18,912 NONTAXABLE BENEFITS: $39,818 TOTAL: $257,599 * JOANNE WESTPHAL: BASE COMPENSATION: $154,130 BONUS AND INCENTIVE COMPENSATION: $20,880 OTHER REPORTABLE COMPENSATION: $3,825 RETIREMENT AND OTHER DEFERRED COMPENSATION: $18,956 NONTAXABLE BENEFITS: $17,257 TOTAL: $215,048 Form 990, Part XI, Line 9 Other changes in net assets or fund balances GRANT REFUNDS - 37398; Form 990, Part XII, Line 2c Change of oversight process or selection process THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.